BMJ:电话健康辅导可改善轻度COPD患者生活质量

2018-06-26 zhangfan MedSci原创

研究发现,电话健康辅导不能改善轻度COPD患者的疾病症状,但可提高患者健康相关生活质量

近日研究人员评估了电话健康辅导对轻度慢性阻塞性肺病患者自我管理的效果。

577名医呼吸困难量表评分为1或2分的COPD患者参与研究,随机接受电话健康辅导(n=289)或常规护理(n=288)。辅导以社会认知理论为基础,包括促进戒烟、增加体力活动、药物管理和行动计划,而对照组患者仅能收到一份关于COPD知识的传单。研究的主要终点是圣乔治呼吸问卷(SGRQ-C)评分及12个月健康相关的生活质量。

电话干预的依从性良好:86%的预定呼叫被接听;75%的病人接受了所有4次指导;92%的患者参与6个月随访,89%的患者参与12个月随访,但组间12个月 SGRQ-C总得分差异不显著(平均差异1.3分)。与对照组相比,干预组6个月随访时身体活动增加显著,健康相关生活质量显著提高。

研究发现,电话健康辅导不能改善轻度COPD患者的疾病症状,但可提高患者健康相关生活质量。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1848543, encodeId=778918485438a, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Mon Sep 17 15:41:00 CST 2018, time=2018-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488830, encodeId=cba1148883047, content=<a href='/topic/show?id=69675090ca' target=_blank style='color:#2F92EE;'>#COPD患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5090, encryptionId=69675090ca, topicName=COPD患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852e8475198, createdName=gous, createdTime=Wed Jun 27 23:41:00 CST 2018, time=2018-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=327123, encodeId=115032e12350, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Tue Jun 26 09:04:52 CST 2018, time=2018-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=327110, encodeId=b34532e11031, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Tue Jun 26 08:52:12 CST 2018, time=2018-06-26, status=1, ipAttribution=)]
    2018-09-17 gaoxiaoe
  2. [GetPortalCommentsPageByObjectIdResponse(id=1848543, encodeId=778918485438a, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Mon Sep 17 15:41:00 CST 2018, time=2018-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488830, encodeId=cba1148883047, content=<a href='/topic/show?id=69675090ca' target=_blank style='color:#2F92EE;'>#COPD患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5090, encryptionId=69675090ca, topicName=COPD患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852e8475198, createdName=gous, createdTime=Wed Jun 27 23:41:00 CST 2018, time=2018-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=327123, encodeId=115032e12350, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Tue Jun 26 09:04:52 CST 2018, time=2018-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=327110, encodeId=b34532e11031, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Tue Jun 26 08:52:12 CST 2018, time=2018-06-26, status=1, ipAttribution=)]
    2018-06-27 gous
  3. [GetPortalCommentsPageByObjectIdResponse(id=1848543, encodeId=778918485438a, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Mon Sep 17 15:41:00 CST 2018, time=2018-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488830, encodeId=cba1148883047, content=<a href='/topic/show?id=69675090ca' target=_blank style='color:#2F92EE;'>#COPD患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5090, encryptionId=69675090ca, topicName=COPD患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852e8475198, createdName=gous, createdTime=Wed Jun 27 23:41:00 CST 2018, time=2018-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=327123, encodeId=115032e12350, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Tue Jun 26 09:04:52 CST 2018, time=2018-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=327110, encodeId=b34532e11031, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Tue Jun 26 08:52:12 CST 2018, time=2018-06-26, status=1, ipAttribution=)]
    2018-06-26 明月清辉

    谢谢分享.学习了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1848543, encodeId=778918485438a, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Mon Sep 17 15:41:00 CST 2018, time=2018-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488830, encodeId=cba1148883047, content=<a href='/topic/show?id=69675090ca' target=_blank style='color:#2F92EE;'>#COPD患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5090, encryptionId=69675090ca, topicName=COPD患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852e8475198, createdName=gous, createdTime=Wed Jun 27 23:41:00 CST 2018, time=2018-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=327123, encodeId=115032e12350, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Tue Jun 26 09:04:52 CST 2018, time=2018-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=327110, encodeId=b34532e11031, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Tue Jun 26 08:52:12 CST 2018, time=2018-06-26, status=1, ipAttribution=)]
    2018-06-26 龙胆草

    学习谢谢分享

    0

相关资讯

Chest:可视化估计的冠状动脉钙化可预测COPD患者心血管疾病!

由此可见,CAC的简单视觉评分在预测患有COPD和不患有COPD的吸烟者CAD事件具有很好的效果。

Heart:成人慢性阻塞性肺疾病和心房颤动的特点和结局!

由此可见,在房颤患者中,COPD与较高的症状负担、较差的生活质量以及较差的心血管和出血结局有关。

Chest:急性四氢生物蝶呤改善慢性阻塞性肺疾病患者内皮功能!

由此可见,急性给予BH4能够改善COPD患者的内皮功能,与对照组相似。内皮功能的改善伴随着NOS3磷酸化的增加。BH4可能是改善COPD患者内皮功能和降低心血管疾病风险的一种新的治疗方法。

Eur Respir J:慢性阻塞性肺疾病患者血液嗜酸性粒细胞计数与肺炎住院风险!

在COPD和FEV1<50%预测值的个体中,血液嗜酸性粒细胞计数超过0.34×109个细胞/L与肺炎的高住院风险有关。

Lancet:中国大陆地区COPD发病率及风险因素研究

研究发现,通过肺活量考察中国成人慢性阻塞性肺病的发病率较高,吸烟、空气污染、体重低、儿童慢性咳嗽、父母肺疾病史以及教育程度低都是导致COPD发病的风险因素

阿斯利康的Fasenra未达到晚期COPD研究的主要目标

阿斯利康公司周五(2018年5月11日)报道,用于中度至极重度慢性阻塞性肺疾病(COPD)患者治疗的Fasenra(benralizumab)的III期GALATHEA研究未能达到显著降低症状的主要终点